Allena Pharmaceuticals (NASDAQ:ALNA) has received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $32.90.
Several equities research analysts recently commented on the company. Roth Capital started coverage on Allena Pharmaceuticals in a research report on Monday, April 2nd. They set a “buy” rating and a $61.00 price objective on the stock. Credit Suisse Group lowered their target price on Allena Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday, March 28th. Zacks Investment Research raised Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 11th. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Allena Pharmaceuticals in a report on Wednesday, March 28th. Finally, B. Riley started coverage on Allena Pharmaceuticals in a report on Wednesday, April 25th. They issued a “buy” rating and a $23.50 target price on the stock.
Hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN raised its stake in shares of Allena Pharmaceuticals by 246.4% in the first quarter. Wells Fargo & Company MN now owns 9,336 shares of the company’s stock worth $103,000 after buying an additional 6,641 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Allena Pharmaceuticals in the fourth quarter worth about $102,000. Citadel Advisors LLC bought a new position in shares of Allena Pharmaceuticals in the first quarter worth about $124,000. Deutsche Bank AG bought a new position in shares of Allena Pharmaceuticals in the fourth quarter worth about $118,000. Finally, Needham Investment Management LLC bought a new position in shares of Allena Pharmaceuticals in the fourth quarter worth about $259,000. 82.24% of the stock is currently owned by institutional investors.
Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. analysts forecast that Allena Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.